Activest Wealth Management’s Protalix BioTherapeutics PLX Stock Holding History

Activest Wealth Management’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$828	Hold	300	–	–	﹤0.01%	863
2026 Q2	$699	Hold	300	–	–	﹤0.01%	1014
2026 Q1	$651	Hold	300	–	–	﹤0.01%	1060
2025 Q4	$540	Hold	300	–	–	﹤0.01%	994
2025 Q3	$666	Hold	300	–	–	﹤0.01%	934
2025 Q2	$444	Hold	300	–	–	﹤0.01%	879
2025 Q1	$768	Hold	300	–	–	﹤0.01%	801
2024 Q4	$564	Hold	300	–	–	﹤0.01%	520
2024 Q3	$306	Hold	300	–	–	﹤0.01%	504
2024 Q2	$351	Buy	+300	New	+$354	﹤0.01%	475

Other funds holding PLX

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Activest Wealth Management's PLX Position: Q3 2026 in Review

Activest Wealth Management held its Protalix BioTherapeutics (PLX) position steady in Q3 2026 at 300 shares worth $828. The position accounts for ﹤0.01% of the portfolio, ranked #863.

Activest Wealth Management first reported a position in PLX in Q2 2024 and has held it in 10 quarters since. 48 funds tracked by Wall St. Rank hold PLX as of Q3 2026.

Activest Wealth Management held 300 shares of Protalix BioTherapeutics worth $828 as of Q3 2026.
Activest Wealth Management left its Protalix BioTherapeutics share count unchanged in Q3 2026.
Protalix BioTherapeutics made up ﹤0.01% of Activest Wealth Management's portfolio in Q3 2026, its #863 holding.
Activest Wealth Management first reported a position in Protalix BioTherapeutics in Q2 2024 and has held it in 10 quarters since.
48 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2026.

Based on Activest Wealth Management's 13F filing for Q3 2026, filed 15 Oct 2026.